Body mass index, comorbidities, and hormonal factors in relation to meningioma in an ethnically diverse population: the Multiethnic Cohort. Read more about Body mass index, comorbidities, and hormonal factors in relation to meningioma in an ethnically diverse population: the Multiethnic Cohort.
Using germline variants to estimate glioma and subtype risks. Read more about Using germline variants to estimate glioma and subtype risks.
Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: summary of SNO and ASCO endorsement of the Congress of Neurological Surgeons guidelines. Read more about Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: summary of SNO and ASCO endorsement of the Congress of Neurological Surgeons guidelines.
Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma. Read more about Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma.
Molecular and translational advances in meningiomas. Read more about Molecular and translational advances in meningiomas.
Advances in multidisciplinary therapy for meningiomas. Read more about Advances in multidisciplinary therapy for meningiomas.
Sex-specific gene and pathway modeling of inherited glioma risk. Read more about Sex-specific gene and pathway modeling of inherited glioma risk.
The lomustine crisis: awareness and impact of the 1500% price hike. Read more about The lomustine crisis: awareness and impact of the 1500% price hike.
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. Read more about Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
An oncolytic measles virus-sensitive Group 3 medulloblastoma model in immune-competent mice. Read more about An oncolytic measles virus-sensitive Group 3 medulloblastoma model in immune-competent mice.
